[Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia].
Zhonghua Xue Ye Xue Za Zhi
; 45(1): 18-21, 2024 Jan 14.
Article
em Zh
| MEDLINE
| ID: mdl-38527833
ABSTRACT
Chronic myelomonocytic leukemia (CMML) is a clonal disease derived from bone marrow hematopoietic stem cells, with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo- HSCT) is one of the curable methods for CMML. The outcome of patient transplantation is influenced by various factors such as disease characteristics and comorbidities. Based on the existing prognostic stratification system, screening suitable CMML patients for transplantation and early transplantation is beneficial for their long-term survival. Doctors can evaluate the survival status of CMML patients after transplantation based on the newly developed transplant prognosis model and make targeted medical decisions.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielomonocítica Crônica
/
Transplante de Células-Tronco Hematopoéticas
Limite:
Humans
Idioma:
Zh
Revista:
Zhonghua Xue Ye Xue Za Zhi
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China